Tissue typing, antilymphocyte globulin, and prophylactic graft irradiation in cadaver kidney transplantation.
In a series of 27 recipients of cadaver kidney grafts, 26 were at the time of writing alive, 3 to 25 months after transplantation, and 25 patients were alive with functioning first grafts. The one-year patient survival in 18 patients was 94% and the one-year graft survival was 89%. There was no beneficial correlation between tissue matching and the frequency of major early rejection episodes or graft function 12 or more months after transplantation. Antilymphocyte globulin administration was associated with a lower incidence of early rejection episodes, but this was not statistically significant. A combination of prophylactic graft irradiation and antilymphocyte globulin administration for at least the first two weeks was associated with a significantly reduced frequency of major early rejection episodes and appreciably better graft function at 12 months. This effect could not be ascribed to better tissue matching.
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D003036:Cobalt Isotopes; D003404:Creatinine / Q000097:blood; D005260:Female; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D011878:Radiotherapy; D014181:Transplantation Immunology; D014184:Transplantation, Homologous
D000961:Antilymphocyte Serum; D003036:Cobalt Isotopes; D007166:Immunosuppressive Agents; D003404:Creatinine